Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02409316 · ClinicalTrials.gov registry record · Phase 2
[18F]FES PET/CT in Endocrine Refractory Breast Cancer
A Phase 2 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT02409316: Clinical Trial Phase 2 study, sponsored by University of Pennsylvania.
NCT02409316 is a Phase 2 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02409316, a Phase 2 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
In this study, positron emission tomography (PET/CT) imaging will be used to evaluate estrogen receptor (ER) activity in sites of metastatic disease using the investigational radiotracer \[18F\]fluoroestradiol (FES).
Primary Outcome
Evaluate \[18F\]FES PET/CT uptake as a predictor of progression free survival in endocrine refractory recurrent or metastatic breast cancer patients starting a new therapy regimen including endocrine targeted therapy
Interventions
- DRUG [18F]FES
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-10-15 |
| Est. Completion | 2025-08-01 |
| Phase | Phase 2 |
Why NCT02409316 stopped before completion
NCT02409316 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which [18F]FES is the first listed.
NCT02409316 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02409316 about?
NCT02409316 is a clinical study titled "[18F]FES PET/CT in Endocrine Refractory Breast Cancer". In this study, positron emission tomography (PET/CT) imaging will be used to evaluate estrogen receptor (ER) activity in sites of metastatic disease using the investigational radiotracer \[18F\]fluoroestradiol (FES).
What is the current status of trial NCT02409316?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2015-10-15. Estimated completion is 2025-08-01.
What interventions are being tested in trial NCT02409316?
The interventions under investigation include: [18F]FES (DRUG).
Who is sponsoring clinical trial NCT02409316?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02409316's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI